Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0N5YA
|
||||
Former ID |
DAP000133
|
||||
Drug Name |
Repaglinide
|
||||
Synonyms |
Actulin; GlucoNorm; NovoNorm; Prandin; Repaglinida; Repaglinidum; Glaxo Wellcome brand of replaginide; Novo Nordisk brand of repaglinide; Repaglinide [USAN]; Novo Nordisk brand 2 of repaglinide; AG-EE 388; AG-EE 388 ZW; AG-EE 623 ZW; AGEE-623ZW; GlucoNorm (TN); NN-623; NovoNorm (TN); Prandin (TN); Repa-glinide; Repaglinida [INN-Spanish]; Repaglinidum [INN-Latin]; SMP-508; AG-EE-388; AG-EE-623 ZW; Prandin, GlucoNorm, NovoNorm, Repaglinide; Repaglinide (JAN/USP/INN); Repaglinide, (+-)-isomer; (+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic acid; (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid; (S)-2-Ethoxy-4-(2-((methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; (S)-2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)-phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; 111GE012; 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid; 2-ethoxy-4-(2-{[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino}-2-oxoethyl)benzoic acid; 2-ethoxy-4-[2-({(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid; 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid; 2-ethoxy-N-(alpha-(2-methyl-1-propyl)-2-piperidinobenzyl)-4-carbamoylmethylbenzoic acid
|
||||
Drug Type |
Small molecular drug
|
||||
Therapeutic Class |
Hypoglycemic Agents
|
||||
Company |
Novo Nordisk
|
||||
Structure |
Download2D MOL |
||||
Formula |
C27H36N2O4
|
||||
InChI |
InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1
|
||||
InChIKey |
FAEKWTJYAYMJKF-QHCPKHFHSA-N
|
||||
CAS Number |
CAS 135062-02-1
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
9872, 7847660, 7980507, 8190080, 11112894, 11467074, 11468194, 11486642, 12014667, 14808699, 14833410, 24724596, 26719812, 43122707, 46386564, 46508150, 47425572, 48244693, 48319772, 48395177, 48416511, 49648522, 49699266, 49888451, 50100536, 52108264, 53789672, 57315871, 81092844, 85788088, 92125938, 92308165, 92308498, 92719265, 93166496, 99218180, 99431925, 99437146, 103394824, 103914669, 104041348, 104179029, 104335174, 117545849, 117873275, 121363609, 124659000, 124757239, 124799919, 125164043
|
||||
SuperDrug ATC ID |
A10BX02
|
||||
SuperDrug CAS ID |
cas=135062021
|
||||
Target and Pathway | |||||
Target(s) | Sulfonylurea receptor 1 | Target Info | Blocker | [535457], [535492], [537390] | |
SUR2-type K(ATP) channel | Target Info | Blocker | [535457], [535492], [537390] | ||
Pathway Interaction Database | FOXA2 and FOXA3 transcription factor networks | ||||
PathWhiz Pathway | Muscle/Heart Contraction | ||||
Pancreas Function | |||||
WikiPathways | Potassium Channels | ||||
Integration of energy metabolism | |||||
References | |||||
Ref 538328 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 077571. | ||||
Ref 541921 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6841). | ||||
Ref 535457 | Pharmacological modulation of K(ATP) channels. Biochem Soc Trans. 2002 Apr;30(2):333-9. | ||||
Ref 535492 | Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet. 2002;41(7):471-83. | ||||
Ref 537390 | Metformin/Repaglinide (PrandiMet) for type 2 diabetes. Med Lett Drugs Ther. 2009 Jun 1;51(1313):41-3. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.